



Terns to Present at the Cowen 41st Annual Healthcare Conference

February 23, 2021

FOSTER CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be presenting at the Cowen 41st Annual Healthcare Conference on Tuesday, March 2 at 9:50 a.m. ET.

A live audio webcast of the presentation will be available [here](#) and on Terns' website at <http://ir.ternspharma.com/>. A replay of the webcast will be archived on Terns' website for 30 days following the presentation.

Terns will also participate in a NASH panel at the conference on Tuesday, March 2 from 12:50-1:50 p.m. ET.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns' [programs](#) are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. For more information, please visit www.ternspharma.com.

US Media Contact:

Investor Relations Contact:
Mark Vignola
investors@ternspharma.com

Media Contact:

Cory Tromblee
media@ternspharma.com